Incretin Lawyers

Incretin drugs stimulate a hormone in the gut that tells the pancreas to produce more insulin, which reduces blood sugar levels.

Victoza, Byetta, Januvia and Janumet are part of a class of diabetes treatments called “incretins”.

Clinical studies and adverse experience reports began to indicate that these products were associated with increased risk of inflammation of the pancreas, known as pancreatitis, which can be deadly and lead to pancreatic cancer. In 2009, the U.S. Food & Drug Administration ordered the manufacturers of these drugs to warn doctors and patients of the risk of pancreatitis. It is alleged that the manufacturers of these drugs did not adequately warn doctors and patients about the associated pancreatic cancer risk. We are handling these complaints from these companies.

In 2011, FDA data indicated that patients on these drugs reported nearly three times the rate of pancreatic cancer, as opposed to users of other diabetes drugs. However, their rates of other cancers were the same; this suggests that the elevated pancreatic cancer rate is unrelated to environmental exposure or other factors, but is more likely to be because of the incretin drugs.